Biorce ESP SL

Biorce, based in Spain, is a provider of advanced clinical AI solutions aimed at enhancing drug development processes for pharmaceutical companies and research organizations. Founded in 2024, by Pedro Coelho, Biorce operates from Barcelona, Spain, focusing on innovative clinical solutions. The company most recent funding round occurring on January 2026, where it raised USD 52 million led by DST Global Partners, with participation from Endeavor Catalyst, YZR, Quantum Light, Outsized Ventures and Mustard Seed Maze. Biorce's primary offering is its Clinical AI Assistant, known as Jarvis, designed to enhance drug development processes through artificial intelligence.

Jarvis facilitates smart study design, protocol development, feasibility analysis, and targeted patient recruitment, thereby streamlining the clinical trial process for pharmaceutical companies and research organizations. This innovative tool empowers patients by helping them identify available clinical trials, thereby reducing the burden of finding relevant studies that suit their medical needs. Biorce primarily targets the pharmaceutical and healthcare sectors, aiming to improve patient engagement and optimize trial efficiency. The company's products serve clients across various geographical markets, including North America, Europe, and select regions in Asia, catering to a diverse range of end users from researchers to patients seeking trial participation.

Biorce’s revenue model primarily revolves around subscriptions for its Clinical AI Assistant, Jarvis, which is offered to pharmaceutical companies and clinical research organizations. Clients engage in annual contracts that provide continuous access to the platform, enabling them to leverage its capabilities for multiple clinical trials throughout the subscription period. Additionally, Biorce may establish partnerships with research institutions, further enhancing its service offerings and generating collaborative revenue streams. Specific pricing plans for the Jarvis platform are customized based on client needs and the scale of implementation, allowing for flexibility in transaction structures.

By delivering a robust AI solution, Biorce aims to strengthen its position in the biopharmaceutical industry while facilitating more efficient drug development processes for its clients. In January 2026, Biorce raised USD 52 million series A funding from DST Global Partners, with participation from Norrsken VC, YZR and Mustard Seed Maze. The company plans to utilize this funding to expand its sales operations in the United States, increase product development capacity, and enhance organizational scale across existing markets. Specific expansion strategies include introducing new features for Jarvis and targeting additional geographic regions, although the details on release dates and specific regions are yet to be disclosed.